Proceedings of the 1st biannual bridging the gaps in lung cancer conference
Uložené v:
| Názov: | Proceedings of the 1st biannual bridging the gaps in lung cancer conference |
|---|---|
| Autori: | Narjust Florez, Sandip P Patel, Heather Wakelee, Lyudmila Bazhenova, Erminia Massarelli, Ravi Salgia, Brendon Stiles, Solange Peters, Jyoti Malhotra, Shirish M Gadgeel, Jorge J Nieva, Michelle Afkhami, Fred R Hirsch, Matthew Gubens, Tina Cascone, Benjamin Levy, Joshua Sabari, Hatim Husain, Patrick C Ma, Leah M Backhus, Puneeth Iyengar, Percy Lee, Russell Miller, Jacob Sands, Edward Kim |
| Zdroj: | Oncologist The oncologist, vol. 30, no. 2 Oncologist, vol 30, iss 2 |
| Informácie o vydavateľovi: | Oxford University Press (OUP), 2024. |
| Rok vydania: | 2024 |
| Predmety: | clinical decision-making, controversies, Tumor, Lung Neoplasms, Carcinoma, Lung Cancer, lung cancer diagnosis, unanswered questions, lung cancer treatment, Humans, Lung Neoplasms/therapy, Lung Neoplasms/pathology, Lung Neoplasms/genetics, Carcinoma, Non-Small-Cell Lung/therapy, Carcinoma, Non-Small-Cell Lung/genetics, Carcinoma, Non-Small-Cell Lung/pathology, Immunotherapy/methods, ErbB Receptors/genetics, Mutation, Molecular Targeted Therapy/methods, Biomarkers, Tumor/genetics, lung cancer management, ErbB Receptors, Carcinoma, Non-Small-Cell Lung, Biomarkers, Tumor, Immunotherapy, Molecular Targeted Therapy, Non-Small-Cell Lung, Biomarkers |
| Popis: | Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances in treatment. Although recent success in developing targeted and immunotherapies for lung cancer has benefitted patients, it has also expanded the complexity of potential treatment options for health care providers. To aid in reducing such complexity, experts in oncology convened a conference (Bridging the Gaps in Lung Cancer) to identify current knowledge gaps and controversies in the diagnosis, treatment, and outcomes of various lung cancer scenarios, as described here. Such scenarios relate to biomarkers and testing in lung cancer, small cell lung cancer, EGFR mutations and targeted therapy in non-small cell lung cancer (NSCLC), early-stage NSCLC, KRAS/BRAF/MET and other genomic alterations in NSCLC, and immunotherapy in advanced NSCLC. |
| Druh dokumentu: | Article Other literature type |
| Popis súboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1549-490X 1083-7159 |
| DOI: | 10.1093/oncolo/oyae228 |
| Prístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/39237103 https://serval.unil.ch/notice/serval:BIB_A6408ED80877 http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_A6408ED808779 https://serval.unil.ch/resource/serval:BIB_A6408ED80877.P001/REF.pdf https://escholarship.org/uc/item/0n07x907 https://escholarship.org/content/qt0n07x907/qt0n07x907.pdf |
| Rights: | CC BY URL: http://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Prístupové číslo: | edsair.doi.dedup.....47b0af6d6432de0303cf25a66ab9c9a2 |
| Databáza: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances in treatment. Although recent success in developing targeted and immunotherapies for lung cancer has benefitted patients, it has also expanded the complexity of potential treatment options for health care providers. To aid in reducing such complexity, experts in oncology convened a conference (Bridging the Gaps in Lung Cancer) to identify current knowledge gaps and controversies in the diagnosis, treatment, and outcomes of various lung cancer scenarios, as described here. Such scenarios relate to biomarkers and testing in lung cancer, small cell lung cancer, EGFR mutations and targeted therapy in non-small cell lung cancer (NSCLC), early-stage NSCLC, KRAS/BRAF/MET and other genomic alterations in NSCLC, and immunotherapy in advanced NSCLC. |
|---|---|
| ISSN: | 1549490X 10837159 |
| DOI: | 10.1093/oncolo/oyae228 |